Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $2.54 million. The enterprise value is -$779,063.

Market Cap	2.54M
Enterprise Value	-779,063

Important Dates

The next estimated earnings date is Wednesday, September 10, 2025, after market close.

Earnings Date	Sep 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 800,954 shares outstanding. The number of shares has increased by 294.83% in one year.

Current Share Class	800,954
Shares Outstanding	800,954
Shares Change (YoY)	+294.83%
Shares Change (QoQ)	+56.24%
Owned by Insiders (%)	0.76%
Owned by Institutions (%)	2.06%
Float	717,145

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.59
P/TBV Ratio	0.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.44

Current Ratio	5.44
Quick Ratio	4.63
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-221.65

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-106.08%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-121.98%
Revenue Per Employee	n/a
Profits Per Employee	-$603,848
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -91.47% in the last 52 weeks. The beta is -0.31, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.31
52-Week Price Change	-91.47%
50-Day Moving Average	3.66
200-Day Moving Average	8.85
Relative Strength Index (RSI)	46.77
Average Volume (20 Days)	242,387

Short Selling Information

The latest short interest is 87,004, so 10.86% of the outstanding shares have been sold short.

Short Interest	87,004
Short Previous Month	136,103
Short % of Shares Out	10.86%
Short % of Float	12.13%
Short Ratio (days to cover)	0.03

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.21M
Pretax Income	-9.95M
Net Income	-4.23M
EBITDA	-4.16M
EBIT	-4.21M
Earnings Per Share (EPS)	-$14.47

Full Income Statement

Balance Sheet

The company has $3.36 million in cash and n/a in debt, giving a net cash position of $3.36 million or $4.19 per share.

Cash & Cash Equivalents	3.36M
Total Debt	n/a
Net Cash	3.36M
Net Cash Per Share	$4.19
Equity (Book Value)	3.45M
Book Value Per Share	5.36
Working Capital	3.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$7.31 million and capital expenditures -$90,000, giving a free cash flow of -$7.40 million.

Operating Cash Flow	-7.31M
Capital Expenditures	-90,000
Free Cash Flow	-7.40M
FCF Per Share	-$9.23

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-294.83%
Shareholder Yield	-294.83%
Earnings Yield	-163.89%
FCF Yield	-286.78%

Analyst Forecast

The average price target for Alzamend Neuro is $180.00, which is 5,578.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$180.00
Price Target Difference	5,578.23%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	27.15%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 12, 2025. It was a reverse split with a ratio of 0.1111111:1.

Last Split Date	May 12, 2025
Split Type	Reverse
Split Ratio	0.1111111:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1